Dr Vicki Sato to be appointed to Galapagos' Board of Directors

01-Apr-2011 - Belgium

Galapagos NV announced that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011.

Dr Sato was President of Vertex Pharmaceuticals from 2000 to 2005, where she led research and development, business and corporate development, commercial operations, legal and finance.  Drugs and drug candidates for treating cystic fibrosis, HCV infection, AIDS, inflammation and cancer were begun under her leadership.  Prior to her role as President, she held various positions at Vertex including Chief Scientific Officer, Senior Vice President of R&D, and Chair of the Scientific Advisory Board.  Before joining Vertex, Dr Sato was Vice President of Research at Biogen, Inc, where she also participated in the Executive Management of the company and served as a member of the Scientific Board.  Currently, Dr Sato is a board member at Bristol Myers Squibb Company, PerkinElmer Corporation, Alnylam Pharmaceuticals, Prize4Life and the Broad Institute (Board of Scientific Counselors).  Dr Sato is Professor of Management Practice at Harvard Business School and Professor of the Practice in the Department of Molecular and Cell Biology, Harvard University.  She also serves as a business advisor to Atlas Venture and other enterprises in the biotechnology and pharmaceutical industries.  Dr Sato holds an AB from Radcliffe College and AM and PhD degrees from Harvard University and completed postdoctoral work at the University of California Berkeley and Stanford Medical Center.

It will be proposed to the AGM that Dr Sato's mandate as a Galapagos Board member last until the 2014 annual shareholders' meeting.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances